Document:

EX-4.26.1

 Exhibit 4.26.1 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and
(ii) would be competitively harmful if publicly disclosed. 
 Amendment No. 1 to the License, Development and Commercialization
Agreement 
 This First Amendment (the “Amendment Agreement”) to the License, Development and Commercialization Agreement effective as
of March 6, 2019 (the “Initial License Agreement”), shall become effective as of March 4, 2020 (the “Effective Date of the Amendment”) by and between Les Laboratoires Servier, a corporation incorporated
under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a corporation incorporated under the laws of France having its
principal place of business at 50 rue Carnot, 92150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”) and Cellectis SA, a company incorporated under the laws of France having a
principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.”

 RECITALS 
 WHEREAS, the Parties
have entered into the Initial License Agreement, dated as of March 6, 2019; and 
 WHEREAS, the Parties hereto desire to amend the Initial
License Agreement to grant to Servier exclusive license to CD19 Target on the terms and subject to the conditions set forth herein. 
 NOW THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree to amend the Initial License Agreement as follows: 
  

	1.	 Definitions.  

 

	 	(a)	 Capitalized terms or derivatives thereof (verbs, nouns, singular, plural) when used in this Amendment Agreement
and not defined herein, will have the meanings set forth in the Initial License Agreement. 

  

	 	(b)	 Annex I of the Initial License Agreement is hereby amended to add the following definitions:

  

	 	(c)	 The definition of “Development Plan” in A.22. of Annex I to the Initial License Agreement is
deleted in its entirety. All references to the Development Plan in the remaining provisions shall be deleted. 

“Indication” means any separate and distinct human disease or medical condition defined in a way that is well recognized in
clinical practice and which is covered by a Competent Authority Approval as a result of or in connection with a specific clinical trial conducted in that indication. For the avoidance of doubt, modifications to the summary of product
characteristics, other than the disease or medical condition, with respect to the Competent Authority Approval of a first indication, due to new quality, safety, pre-clinical, clinical or pharmacovigilance findings, do not qualify as a separate
indication. Treatment, modulation or prophylaxis of the same disease, regardless of the patient population, shall be treated as the same indication. For sake of clarity, [***] and [***] are each a separate Indication. 

 
 1/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 “UCART19 V3” or “ALLO501A” mean the UCART19 Product
whereby the CD19 CAR is devoid of any suicide switch, and which includes a TRAC gene knock out and CD52 gene knock out. 
  

	 	(d)	 Section 3.10 of the Initial License Agreement is hereby amended to delete the definition of “Primary
Target” and substitute it with the following: 

 “Primary Target” means CD19 Target
[***]. 
  

	 	(e)	 The definition of “UCART19 Product” or “UCART19 Candidate Product” in
A.71 in Annex I to the Initial License Agreement is hereby amended and restated in its entirety with the following: 

“UCART19 Product” means any human allogenic CAR T-cell product engineered to express a single-chain CAR directed against the
CD19 Target using Cellectis IP (including without limitation TAL Nuclease Cellectis Patents), and gene edited exclusively using TAL nucleases, including without limitation the UCART19 V3 Product. 

 

	 	(f)	 The definition of “Change of Control” in A.10 of Annex I to the Initial License Agreement is hereby
amended such that the phrase “begins to control” is deleted and replaced with “acquires control of”. 

  

	 	(g)	 The definition of “Option Date” in A.42 of Annex I to the Initial License Agreement is hereby amended
by deleting it in its entirety. 

  

	 	(h)	 In Annex I of the Initial License Agreement, the following definitions are hereby amended and restated in their
entirety with the following: “means UCART19 Product”: 

 “Candidate Product” in A.5 

“Pre-Candidate Product” in A.47 

“Servier Product” in A.57 

“Subsequent Product” in A.61 

“Substitute Product” in A.62 

The remaining Sections in ANNEX I “DEFINITIONS” shall be renumbered accordingly. 

 

	2.	 Amendments to Article 2: Management. 

 

	 	(a)	 Article 2 of the Initial License Agreement is hereby amended to delete the entirety of Article 2, except for
Sections 2.2, 2.4, 2.7, 2.8, 2.10, 2.11, 2.12 and 2.13. All references and provisions specifically related to the committees other than the Joint Executive Committee (such as the Joint Steering Committee and Joint Research and Development Committee)
in the remaining provisions shall be deleted. 

  

	 	(b)	 Section 2.2 of the Initial License Agreement is hereby amended as follows: 

 
 2/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 2.2. Alliance Managers. Each of Servier and Cellectis shall appoint one or two senior
representatives who possess a general understanding of development, regulatory, manufacturing and commercialization matters to act as its respective alliance manager(s) for this relationship (each, an “Alliance Manager”). Each Party may
replace its respective Alliance Manager(s) at any time upon written notice to the other in accordance with this Agreement. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager. Each Alliance
Manager shall be charged with creating and maintaining a collaborative work environment within and among the Joint Executive Committee. Consistent with Section 2.10, each Alliance Manager, on behalf of the applicable Party’s Co-Chairperson
of the Joint Executive Committee, will also be responsible for: 
  

	 	(a)	 serving as a primary point of contact with respect to exchange of data and information regarding the UCART19
Products; 

  

	 	(b)	 ensuring that the governance procedures and rules set forth herein are complied with; 

 

	 	(c)	 identifying and raising disputes to the JEC for discussion in a timely manner; 

 

	 	(d)	 planning and coordinating internal and external communications in accordance with the terms of this Agreement;
and 

  

	 	(e)	 if necessary, organize meetings between the Parties in order to discuss operational matters relevant to the
performance of the Agreement with respect to [***]. 

 The Alliance Managers shall be entitled to attend all JEC meetings.
Consistent with Section 2.10, each Alliance Manager may bring any matter to the attention of the JSC or JEC where such Alliance Manager reasonably believes that such matter requires attention of the JSC or JEC. 

At the latest ten (10) days after the Effective Date, to the extent the Parties have not already done so in accordance with the Original
Agreement, each Party shall appoint and notify the other Party of the identity of their representatives to act as alliance managers under this Agreement. 
  

	 	(c)	 Section 2.4.2. of the Initial License Agreement is hereby amended as follows: 

“2.4.2. Function and Powers of the JEC. The JEC shall (a) manage the overall collaboration between the Parties
and major changes to the collaboration requiring amendments to this Agreement and (b) resolve disputed matters that may arise in the performance of the Agreement.” 
  

	 	(d)	 Section 2.4.3 of the Initial License Agreement is hereby amended as follows: 

“2.4.3. Frequency of Meetings. The Joint Executing Committee shall meet once yearly, and such meetings may be conducted by
telephone, videoconference or in person as determined by the Co-Chairpersons. As appropriate, provided that not less than two (2)
  

3/14 
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

 
Business Days’ prior written notice has been given to the other Party, and subject to such other Party’s approval (not to be unreasonably withheld, delayed or retained), other employees
of the Parties may attend Joint Executive Committee meetings as observers. Either Party may also call a special meeting of a Joint Executive Committee (in person, by videoconference or teleconference) by at least ten (10) Business Days’
prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the Joint Executive Committee no later than
ten (10) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision.” 
  

	3.	 Amendments to Article 3: Development Activities. 

 

	 	(a)	 Article 3 of the Initial License Agreement is hereby amended by deleting the following sections in their
entirety: Sections 3.1, 3.2, 3.3, 3.4, 3.7, 3.8 and 3.9. 

  

	 	(b)	 Section 3.5 of the Initial License Agreement is hereby amended by deleting “after having exercised
its Option to License in relation to such Product” in the first sentence of Section 3.5. 

  

	 	(c)	 Section 3.6 of the Initial License Agreement is hereby amended and restated in its entirety with the
following: 

  

	 	3.6	 Opt-Out 

  

	 	3.6.1	 Servier hereby confirms it will not pursue the following Programs: [***]. 

 

	 	3.6.2	 Any products related to [***] are considered as terminated under this Agreement. Consequently, such products
and Programs are considered as terminated and the rights granted by Cellectis to Servier under the corresponding Program shall automatically terminate and Cellectis shall have no further obligations towards Servier with respect to such products. For
sake of clarity, dispositions of Section 11.3 shall apply regarding [***]. 

  

	4.	 Amendments to Article 4: Grant of Rights to Servier. 

 

	 	(a)	 Sections 4.1, 4.2(a) and 4.2(b) of the Initial License Agreement are hereby amended and restated in their
entirety with the following: 

 4.2 License to Develop and Commercialize UCART19 Products. 

(a) Upon the Effective Date of the Amendment Agreement, Cellectis shall grant to Servier, until the end of the Term, an exclusive worldwide
license, with the right to grant sublicenses on the terms set out in Section 4.1(b), under Cellectis IP other than [***], to Develop, have Developed, Manufacture, have Manufactured, and Commercialize UCART19 Products, in the Field in the
Territory. 
 (b) Servier shall promptly inform Cellectis of any Sublicensee and all sublicensees will include all material rights and
obligations due to Cellectis under the Agreement. 
  
 4/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 The license under the [***] shall be governed by the license grants set
forth in Sections 4.2(d) and (e). 
  

	 	(b)	 Subsection 4.2(c) of the Initial License Agreement is hereby amended by deleting “Upon Servier’s
exercise of the Option to License for a given Product” in the first sentence of Subsection 4.2(c). 

  

	 	(c)	 Subsection 4.2(d) of the Initial License Agreement is hereby amended by deleting “Upon Servier’s
exercise of its Option to License for a given Product, and” in the first sentence of Subsection 4.2(d). 

  

	 	(d)	 Subsection 4.2(e) of the Initial License Agreement is hereby amended by deleting “Upon exercise of the
Option to License on a Product-by-Product basis, and” in the first sentence of Subsection 4.2(e). 

  

	 	(e)	 Article 4 of the Initial License Agreement is hereby amended by adding the following as Section 4.4:

 4.4 Responsibilities Regarding UCART19 Products. 

 

	 	(a)	 New UCART19 Products. 

Servier shall inform Cellectis of its intention to develop any UCART19 Product other than [***] (a “New UCART19 Product”) in writing
and promptly, but in no event later than thirty (30) days after Servier’s decision to develop such New UCART19 Product has been formalized. 

Prior to initiation of any IND/IMPD Enabling Data Package relating to such New UCART19 Product, Servier shall provide a detailed description of
[***]. Should Cellectis reasonably demonstrate that [***] proposed by Servier would have a material adverse patient safety impact that would be reasonably likely to materially affect Cellectis’ own CART products, then such Product construct
will not be advanced, unless otherwise agreed upon between the Parties. Cellectis shall provide its comments no later than [***] following provision by Servier of the description of the [***]. 

Cellectis and Servier shall also negotiate in good faith to mutually agree on [***] with respect to such New UCART19 Product as applicable.
Once mutually agreed, and upon Servier’s request, Cellectis shall grant to Servier an exclusive (even as to Cellectis), worldwide license under [***] related to such agreed upon additional [***], to Develop, have Developed, Manufacture, have
Manufactured, and Commercialize New UCART19 Products in the Field and the Territory. For the avoidance of doubt, such an exclusive license shall not otherwise affect or limit Cellectis’ rights in the [***]. At Servier’s written direction,
Cellectis shall also grant to Servier’s US Partner a parallel license under these [***] in accordance with Sections 4.2(d) and (e) of the Agreement. 

Servier and its US Partner are responsible for the Development, Manufacture and Commercialization of UCART19 Products, and Cellectis shall not
be responsible for any Development activities. 
  

	 	(b)	 Servier Responsibilities Related to Information Sharing. 

For each clinical trial involving a UCART19 Product, Servier shall promptly provide Cellectis with [***]. Servier shall also promptly provide
Cellectis [***]. 
  
 5/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 For each Phase 1 clinical trial involving a UCART19 Product, Servier shall regularly inform
Cellectis of the progress of [***] and shall provide Cellectis on an ongoing basis with a copy of [***]. Such updates shall be provided at least [***], or in case of material event or data, promptly after occurrence of such material event or data.

 For each clinical trial other than a Phase 1 clinical study involving a UCART19 Product, Servier shall regularly inform Cellectis of [***]
and would provide Cellectis on an ongoing basis with a copy of [***]. Such updates shall be provided [***], or in case of material event or data, promptly after occurrence of such material event or data. 

Servier shall regularly inform Cellectis of the progress of the development of each [***], including providing a regular update of the [***],
as well as [***] and respond to any reasonable request from Cellectis in connection with [***]. Such updates shall be provided at least [***], or in case of material event or data, promptly after occurrence of such material event or data. 

Servier shall consult with Cellectis regarding [***]. 

Cellectis shall have the right to use [***] provided to it by Servier in the course of [***] UCART19 Products for the development of its own
products. For clarity, such information shall qualify as Servier Confidential Information but that designation shall not preclude the use by Cellectis as contemplated by the preceding sentence; provided that Cellectis complies with Article 8
of the Agreement. 
 Notwithstanding anything to the contrary, the information sharing obligations provided above shall be made in
accordance, and subject to, applicable laws. [***]. 
 Servier shall use Commercially Reasonable Efforts to Develop and Commercialize UCART19
Products [***], and to exploit the license granted herein, and will deliver annually to Cellectis by [***] a written report detailing its efforts and plans to develop and commercialize such UCART19 Products for the prior calendar year. 

 

	5.	 Amendment to Article 5: Transfer and Supply. 

Article 5 of the Initial License Agreement is hereby amended by deleting it in its entirety. 

 

	6.	 Amendment to Section 6.2 : Reimbursement of costs incurred by Cellectis.  

Section 6.2 of the Initial License Agreement is hereby amended by deleting it in its entirety. 

 

	7.	 Amendment to Section 6.4: Reports and Audits. 

Subsection 6.4(a) of the Initial License Agreement is hereby amended by deleting “After each Option Date, and” in the first sentence.

  

	8.	 Amendment to Section 7.1: Inventions and Intellectual Property Ownership. 

Section 7.1 of the Initial License Agreement is hereby amended by adding the following subsection: 

 
 6/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 (e) UCART19 Inventions. [***] and any [***] UCART19 Product, all inventions made up
and until the IND filing (the “UCART19 Inventions”) shall be considered as Cellectis IP for the sole purpose of the royalties payment. For avoidance of doubt, for any other purpose than the royalties payment, UCART19 Inventions
shall qualify as Servier IP and related Patent applications shall be filed in the name of Servier or Servier and its US Partner. 
 Should
the Parties mutually agree on Cellectis to conduct any pre-clinical research activities up to the IND Enabling Data Package, Servier shall grant an exclusive, worldwide, free, sublicensable license under the UCART19 Inventions and related know-how
improving Cellectis IP that are not specifically and solely related to the UCART19 Products to exploit such invention for any purpose, except for the Development, Manufacture and/or Commercialization of any Product within a [***]. 

Servier shall grant a non-exclusive, worldwide, free, sublicensable license under all UCART19 Inventions and related know-how improving
Cellectis IP that are not specifically and solely related to the UCART19 Products to exploit such invention for any purpose, except for the Development, Manufacture and/or Commercialization of any Product within a [***]. 

For clarity, the UCART19 Inventions and related know-how referred to above includes any relevant intellectual property rights controlled by
Servier pursuant to the US Partner-Servier Agreement. 
  

	9.	 Amendments to Section 7.2: Patent Prosecution. 

 

	 	(a)	 Subsection 7.2(a) of the Initial License Agreement is hereby amended by deleting the second and third
paragraphs. 

  

	 	(b)	 Subsection 7.2(a) of the Initial License Agreement is hereby amended and restated by deleting “After
exercise of the Option to License, with respect to Product Patents,” in the first sentence of the fourth paragraph and replacing it with the following: 

“[***] (“Product Patents”)” 
  

	 	(c)	 Subsection 7.2(c) of the Initial License Agreement is hereby amended and restated by deleting it in its
entirety. 

  

	10.	 Amendment to Section 7.4: Defense and Settlement of Third Party Claims. 

Section 7.4 of the Initial License Agreement is hereby amended by deleting the first paragraph in its entirety and by deleting the
following in the first sentence of the second paragraph: 
 “After Servier has exercised its Option to License for a given
Product,” 
  

	11.	 Amendment to Section 7.5: Enforcement. 

Section 7.5 of the Initial License Agreement is hereby amended by deleting the following in its entirety: 

“Prior to Servier’s exercise of its Option to License 

 
 7/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 Cellectis shall have the sole right, but not the obligation, to enforce Cellectis IP and
Joint IP against any actual, alleged or threatened infringement or misappropriation by Third Parties in the Territory, at Cellectis’ sole cost. 

From and after Servier’s exercise of its Option to License” 

 

	12.	 Amendments to Section 9.2: Representations and Warranties of Cellectis. 

 

	 	(a)	 Section 9.2 of the Initial License Agreement is hereby amended by deleting Section 9.2.5 in its
entirety. 

  

	 	(b)	 Section 9.2 of the Initial License Agreement is hereby amended by deleting the following in its entirety:

 “[***]” 
  

	13.	 Amendment to Section 11.3.2. 

Section 11.3.2 of the Initial License Agreement is hereby amended by deleting “and [***] Candidate Products or Products”. 

 

	14.	 Amendment to Article 12: Change of Control. 

Article 12 of the Initial License Agreement is hereby amended and restated in its entirety with the following: 

12.1. Change of Control. Cellectis shall give Servier written notice within ten (10) days after the public announcement or
disclosure of any proposed Change of Control of Cellectis if Cellectis’ contemplated successor conducts in a material respect directly or indirectly research, development, manufacturing or commercialization activities on Primary Target or on
any other CAR-T products (except products developed by Cellectis at the time Cellectis provides Servier such written notice) within the Indications developed by Servier at the time of the proposed Change of Control (“Servier’s
Competitor”) or has direct or indirect control over a Servier’s Competitor (the “Change of Control Notice”). For the avoidance of doubt, Cellectis shall have the right to serve such notice in advance of public
announcement or disclosure of said Change of Control, in which case Servier shall treat that information as strictly confidential. Upon such notice, Servier shall have the right to acquire for one lump-sum payment (the “Buyout
Payment”), an exclusive fully paid up worldwide license, with the right to grant sublicense, under Cellectis IP other than the [***] to Develop, have developed, manufacture, have manufactured and Commercialize in the Field any UCART19
Products in the Territory, pursuant to the section 12.2 below (the “Buy-Out”). With respect to [***], Cellectis shall deliver to Servier a binding undertaking from Cellectis’ successor providing that such successor undertakes
to comply with the provisions of the Agreement, without additional payment due by Servier or any other conditions more restrictive than the ones provided for in the Agreement. The completion of the Buy-Out shall be subject to actual completion of
the Change of Control, it being specified that if the Buy-Out Payment has been paid prior to completion of the Change of Control, Cellectis will be liable to reimburse Servier within ten (10) days of the decision not to complete the Change of
Control. 
  
 8/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 12.2. Buy-Out. If Servier exercises its right to Buy-Out, Servier will provide
written notice to Cellectis (a “Buyout Notice”) within fifteen (15) days following the Change of Control Notice. Within ten (10) days following Servier’s provision of the Buyout Notice, the Parties will meet and
negotiate the amount of the Buyout Payment. 
 12.2.1. If the Parties agree on the amount of the Buyout Payment within such ten (10) day
period, then Servier will pay the applicable Buyout Payment to Cellectis (or its successor) within thirty (30) day period. Further to the Buyout, and subject to actual payment of the Buy-Out Payment, the licenses on the Cellectis IP within the
scope of the Buy-Out will be deemed fully paid up. 
 12.2.2. If the Parties fail to agree on an amount of a Buyout Payment within ten
(10) days following the provision of the Buyout Notice, then within two (2) days thereafter each Party will select and pay at its costs one (1) Third Party valuator (such valuators shall be from top-tier, internationally-recognized
investment banks or accounting firms) with relevant expertise to determine the appropriate amount for the Buyout Payment. Each of the Parties will provide to such valuators such information as it deems pertinent and any information requested by such
valuators. Such selected valuators will promptly (and in any event within twenty (20) days after the selection of such valuators) determine their respective valuation of the Buyout Payment amount and provide notice of such amount (and
underlying assumptions and methodology) to each of the Parties. If the amount of the Buyout Payment estimated by one valuator is equal to or less than one hundred twenty percent (120%) of the amount of the Buyout Payment estimated by the other
valuator, then the Buyout Payment shall be equal to the average of the amount proposed by the valuators. If the amount of the Buyout Payment estimated by one valuator is greater than one hundred twenty percent (120%) of the amount of the Buyout
Payment estimated by the other valuator, then the Parties will mutually agree upon a third valuator. In such event, the Buyout Payment determined by the third valuator shall be the Buyout Payment (provided, that the Buyout Payment shall be capped at
the amount of the higher of the Buyout Payments determined by the prior two valuators, and shall not be lower than the amount of the lower of the Buyout Payments determined by the prior two valuators). 

12.2.3. After determination of the Buyout Payment pursuant to Section 12.2.1 or 12.2.2 above, as applicable, Servier will pay the
applicable Buyout Payment to Cellectis (or its successor) within thirty (30) day period. Further to the Buyout, and subject to actual payment of the Buy-Out Payment, the licenses on the Cellectis IP within the scope of the Buy-Out will be
deemed fully paid up. 
  

	15.	 Amendments to Article 13: Miscellaneous. 

 

	 	(a)	 Article 13 of the Initial License Agreement is hereby amended by adding the following as Section 13.12:

 13.12 Payments Under the 2014 Agreement and the Initial License Agreement 

For the sake of clarity, all payments made by Cellectis to Servier under the 2014 Agreement and the Initial License Agreement are
non-refundable. 
  

	 	(b)	 Article 13 of the Initial License Agreement is hereby amended by adding the following as Section 13.13:

  
 9/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 13.13 Acknowledgement of Cellectis.  

Any public reference to a Product falling under the Initial License Agreement, including UCART19 Products, will include language acknowledging
the license granted by Cellectis to Servier and the use of Cellectis’ technologies. 
  

	 	(c)	 Article 13 of the Initial License Agreement is hereby amended by adding the following as Section 13.14:

 13.14 Standstill 

Servier shall, and shall procure that its Affiliates shall, abstain from tendering for, or otherwise trading in, Cellectis securities for a
period of 12 months from the Effective Date, except with the prior consent of Cellectis or as part of the consummation of a bona fide tender offer made pursuant to applicable laws and regulations following a tender offer initiated by a third
party. Servier shall further, and shall procure that its affiliates shall, refrain during a 12-month period, other than with the prior consent of Cellectis, from initiating contact with any person holding or controlling, directly or indirectly, 5%
or more of Cellectis’ shares in connection with a possible acquisition or other form of transfer, immediate or deferred, of all or part of their shares of Cellectis. 
  

	16.	 Amendments to Exhibit 1: Fees, Payments and Royalties. 

 

	 	(a)	 A.1. of Exhibit 1 of the Initial License Agreement is hereby amended such that the following is added to the
end of A.1.: 

 Servier will pay Cellectis the non-refundable sum of twenty-five million euros (25,000,000€) on
the Effective Date of the Amendment Agreement. 
  

	 	(b)	 A.2. of Exhibit 1 of the Initial License Agreement is hereby amended by deleting it in its entirety.

  

	 	(c)	 A.3. (a)-(f) of Exhibit 1 of the Initial License Agreement is hereby amended and restated in its entirety
by the following: 

 (a) Development Milestones. On an Indication-by-Indication basis, Servier shall pay to Cellectis the
following non-refundable milestone payments upon the occurrence of each event: 
  

					
	 Milestone event
	  	Milestone
payment
(in €)	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  
 10/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 For the avoidance of doubt, each milestone payment is payable once per Indication, and no
milestone would be due under this Amendment Agreement for events having occurred prior to the Effective Date of the Amendment Agreement. For further clarity, no milestone related to [***]. All payments that were due and payable under the Initial
License Agreement have been paid by Servier, with the exception [***] which shall remain due and payable and shall be paid immediately. 
  

	 	(d)	 A.3.(g) of Exhibit 1 of the Initial License Agreement is hereby amended and restated in its entirety by the
following: 

 (g) Sublicense Revenues. In the event that Servier grants rights relating to Cellectis IP for the
Development and Commercialization of a Product to a Third Party, Servier shall pay to Cellectis an amount equal to [***] of any and all sums received by Servier from such Third Party as the result of [***] and all other payments made to Servier
pursuant to an option, license or sublicense, shares of stock or other units of equity, payments made to Servier upon fulfillment of designated development objectives, regulatory requirements, or commercial milestones and payments made to Servier
[***]. For avoidance of doubt, subject to Section A.5 of Exhibit 1 (Royalties to Cellectis), [***]. 
  

	 	(e)	 A.4. of Exhibit 1 of the Initial License Agreement is hereby amended and restated in its entirety with the
following: 

 Servier shall pay the following sales milestones on the first time aggregated annual Net Sales of each
UCART19 Product reach the following thresholds: 
  

					
	 First time aggregated annual Net Sales of each UCART19 Product
reaches
	  	Milestone
payment
(in €)	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  

	 	(f)	 A.5. of Exhibit 1 of the Initial License Agreement is hereby amended and restated in its entirety with the
following: 

 In addition to the Milestone payments, during the Royalty Term, Servier shall pay royalties of [***] to
Cellectis on annual Net Sales of the Products. 
  
 11/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

	 	(g)	 A.6. of Exhibit 1 of the Initial License Agreement is hereby amended and restated such that “exercise by
Servier of the exclusive Option to License” is replaced with “Effective Date.” 

  

	 	(h)	 A.7. of Exhibit 1 of the Initial License Agreement is hereby amended by deleting it in its entirety.

  

	17.	 Amendment to Exhibit 5: Servier Target. 

 

	 	(a)	 Exhibit 5 of the Initial License Agreement is hereby amended to delete references to [***].

  

	 	(b)	 The provisions of Section 11.3 of the Initial License Agreement will apply with respect to [***] as if
Servier had exercised its Opt-Out Option with respect to such Targets. Notwithstanding the foregoing, Servier hereby waives its Right of First Refusal in such Targets. 

 

	18.	 The Press Release as set forth in Exhibit A will be released by the Parties within three (3) business days
of signature of this Amendment Agreement. 

  

	19.	 Miscellaneous. Except as expressly provided in this Amendment Agreement, the Initial License Agreement
remains unchanged, and the Initial License Agreement as modified hereby remains in full force and effect. The Amendment Agreement shall not result in a novation of the Initial License Agreement. To the extent of any inconsistency between the
provisions of the Amendment Agreement and the provisions of the Initial License Agreement, the terms of the Amendment Agreement shall govern. The Amendment Agreement shall be governed by and construed in accordance with the laws of France. The
Amendment Agreement may be executed and delivered by facsimile or in .pdf format by electronic mail, and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall
constitute one agreement. 

 IN WITNESS WHEREOF, Cellectis and Servier have caused the Amendment to be executed by their duly
authorized representatives as of the Effective Date. 
  
  

					
	 For Celletis SA,
	 		 	 For Les Laboratoires Servier,

			
	 By: /s/ André Choulika
	 	  
	 	 By: /s/ Eric Falcand

	 Name: André CHOULIKA
	 		 	 Name: Eric FALCAND

	 Title: Chief Executive Officer
	 		 	 Title: Proxy

  

	
	
	
	 By: /s/ Christian Bazantay

	 Name: Christian BAZANTAY

	 Title: Proxy

  
 12/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 For Institut de Recherche Internationales Servier 

 

	
	
	
	 By: /s/ Claude Bertrand

	 Name: Claude Bertrand

	 Title: Executive Vice President of R&D

  
 13/14 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii)
would be competitively harmful if publicly disclosed. 

 Exhibit A 

Press Release 

[Omitted] 
  

14/14 
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.EX-4.27.2

 Exhibit 4.27.2 

SECOND AMENDMENT TO THE 

MANAGEMENT SERVICES AGREEMENT 

This SECOND AMENDMENT TO THE MANAGEMENT SERVICES AGREEMENT (the “Second Amendment”) is made and entered into effective as of
January 29, 2020 by and among Cellectis S.A. (“CLS”), Cellectis, Inc. (“CLI”), Calyxt, Inc. (“CLX”), and Cellectis Biologics, Inc. (“CBL”), each a Party and together the Parties. 

WHEREAS, CLS, CLI and CLX entered into that certain Management Services Agreement dated January 1, 2016, as amended by that certain First
Amendment to the Management Services Agreement dated July 25, 2017 (the “Agreement”); 
 WHEREAS, Cellectis Biologics,
Inc. (“CBL”), a company fully owned by CLI, was incorporated in the State of Delaware in January 18, 2019 and as such is a Party to this Agreement. 

WHEREAS, the Parties have agreed to further amend the Agreement as set forth in this Second Amendment. 

NOW, THEREFORE, in consideration of the agreements and obligations set forth herein and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Parties agree that the Agreement is hereby amended as follows: 
  

	 	1.	 As from July 1, 2019 (i) CBL, CLS, CLI and CLX agree to consider CBL as a Party and Subsidiary to this
Agreement and (ii) CBL hereby agrees to be bound by all terms and conditions of this Agreement. The Parties hereby agree that the Services to be provided by CLS, as Provider, to CBL, as Beneficiary, and the Services to be provided by CBL, as
Provider, to CLS, as beneficiary, are the Services set forth on Exhibit A attached hereto and incorporated herein. 

  

	 	2.	 Exhibit 1 of the Agreement is amended to revise the “Basis of Allocation” for “IT- internal support” and “Human Resources” Services provided by CLS to CLX, to CLI and to CBL from “Number of CLX’s FTE” to “Time Spent”. Such amendment shall be
effective as of July 1, 2019. 

  

	 	3.	 All other provisions of the Agreement not expressly amended herein shall remain in full force and effect.

 * * * * * 

 IN WITNESS WHEREOF, the Parties have caused this Second Amendment to be duly executed by
their respective authorized officers as of the date first written above. 
  

			
	CELLECTIS S.A.
		
	By:	 	 /s/ David Sourdive

		 	Name: David Sourdive
		 	Title: Deputy Chief Executive Officer
	
	CELLECTIS, INC.
		
	By:	 	 /s/ André Choulika

		 	Name: André Choulika
		 	Title: Chief Executive Officer
	
	CALYXT, INC.
		
	By:	 	 /s/ James Blome

		 	Name: James Blome
		 	Title: Chief Executive Officer
	
	CELLECTIS BIOLOGICS, INC.
		
	By:	 	 /s/ André Choulika

		 	Name: André Choulika
		 	Title: Chief Executive Officer

 EXHIBIT A 

 Services performed by Cellectis SA (CLS) on behalf of Cellectis Biologics, Inc. (CBL): 

 

							
	 Types of Services
	  	 Costs and Expenses
	  	 Basis of Allocation of the

Costs and Expenses
	  	 Mark-up

	 Finance
	  	 Salaries and social contribution costs
  

Indirect costs
  
	  	Time spent	  	 4% 
  
  

0%

	 IT – LIMS use
	  	 Salaries and social contribution costs
  

Indirect costs
  
	  	Number of users of the LIMS	  	 4% 
  
  

0%

	 IT – internal support
	  	 Salaries and social contribution costs
  

Indirect costs
  
	  	Time spent	  	 4% 
  
  

0%

	 Human Resources
	  	 Salaries and social contribution costs
  

Indirect costs
  
	  	Time spent	  	 10% 
  
  

0%

	 Legal
	  	 Salaries and social contribution costs
  

Indirect costs
  
	  	Time spent	  	 10% 
  
  

0%

	 R&D
	  	 Salaries and social contribution costs
  

Indirect costs
	  	Time spent	  	 7% 
  
  

0%

 Services performed by Cellectis Biologics, Inc. (CBL) on behalf of Cellectis SA (CLS): 

 

							
	 R&D
	  	 Salaries and social
 contribution costs

 
 Indirect costs
	  	Time spent	  	 7%
  

 
  
 0%

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]